Product information and disease descriptionProduct descriptionProduct information
Access and distribution
4 evidence topics · 5 sources
Centralized in-house manufacture and lot release time of about three weeks
Manufacturing success: participants meeting manufacturing specifications in the phase 2b trial
“Of the 45 patients who met the inclusion criteria, 36 were eligible to be randomized after meeting manufacturing specifications, of whom 20 were assigned to the active Descartes-08 arm, and 16 were assigned to the placebo arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Commercial infrastructure plans
Community clinic administration as a design goal of the product
“To broaden use of CAR T-cells in community clinics and in a frontline setting, we developed a novel CD8+ CAR T-cell product, Descartes-08, with predictable pharmacokinetics for treatment of multiple myeloma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote